Stocksigma LogoStocksigma Logo

Orchid Pharma Reports Strong Q2 FY27 Results and Expansion

Orchid Pharma delivered standalone revenue of ₹341 Cr for Q2 FY27, up 14% YoY, with EBITDA surging 148% YoY to ₹52 Cr as margins expanded to 15%

Orchid Pharma Reports Strong Q2 FY27 Results and Expansion

Orchid Pharma Ltd · Investor Presentation · 17 Nov 2026, 12:22 am

Orchid Pharma Reports Strong Q2 FY27 Results and Expansion Orchid Pharma delivered standalone revenue of ₹341 Cr for Q2 FY27, up 14% YoY, with EBITDA surging 148% YoY to ₹52 Cr as margins expanded to 15%. Consolidated PAT reached ₹28.59 Cr compared to a net loss of ₹0.90 Cr in Q2 FY26. For H1 FY27, consolidated operating cash flow stood at ₹117.78 Cr. Growth initiatives advanced with the amalgamation of Dhanuka Laboratories effective 10th Jul'26, EXBLIFEP licensing partnerships securing $258M in estimated potential across 10 markets, and ongoing CWIP on 7ACA and Cefiderocol projects.

Original exchange filing (PDF)

More announcements from Orchid Pharma Ltd

All Orchid Pharma Ltd announcements